XOMA HOPES NEUPREX NEWS CAN CONVINCE WALL STREET OF LIFE AFTER E5
Executive Summary
Xoma is hoping that a stream of revenues from manufacturing process licensing agreements and a steady flow of news from the development of the bactericidal/permeability increasing protein Neuprex can help the company turn the tide on Wall Street